Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Metadata
Title
Glutaric aciduria type I and kynurenine pathway metabolites: A modified hypothesis
Authors
S. Varadkar
R. Surtees
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Journal of Inherited Metabolic Disease / Issue 6/2004
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1023/B:BOLI.0000045767.42193.97

Other articles of this Issue 6/2004

Journal of Inherited Metabolic Disease 6/2004 Go to the issue

OriginalPaper

Vascular dysfunction as an additional pathomechanism in glutaric aciduria type I

BookReview

Book Reviews: Lysosomal disorders of the brain: Recent advances in molecular and cellular pathogenesis and treatment

OriginalPaper

Development of pathogenic concepts in glutaryl-CoA dehydrogenase deficiency: The challenge

OriginalPaper

Nuclear magnetic resonance spectroscopy in glutaryl-CoA dehydrogenase deficiency

OriginalPaper

Reduction of lysine intake while avoiding malnutrition—Major goals and major problems in dietary treatment of glutaryl-CoA dehydrogenase deficiency

OriginalPaper

Maintenance treatment of glutaryl-CoA dehydrogenase deficiency

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits